"Quinazolinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen.
| Descriptor ID |
D052999
|
| MeSH Number(s) |
D03.633.100.786.830
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolinones".
Below are MeSH descriptors whose meaning is more specific than "Quinazolinones".
This graph shows the total number of publications written about "Quinazolinones" by people in this website by year, and whether "Quinazolinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 6 | 3 | 9 |
| 2018 | 9 | 4 | 13 |
| 2019 | 3 | 3 | 6 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinazolinones" by people in Profiles.
-
A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. Nat Commun. 2021 06 23; 12(1):3907.
-
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021 04 15; 184(8):2167-2182.e22.
-
Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments. Bioorg Med Chem Lett. 2021 05 01; 39:127885.
-
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro. mBio. 2021 01 19; 12(1).
-
PI3Kd Inhibition as a Potential Therapeutic Target in COVID-19. Front Immunol. 2020; 11:2094.
-
Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-d Inhibitor CAL-101. Cancer Invest. 2019; 37(7):311-324.
-
Novel antiacanthamoebic compounds belonging to quinazolinones. Eur J Med Chem. 2019 Nov 15; 182:111575.
-
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leuk Res. 2019 06; 81:88-94.
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
-
Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. J Cell Biochem. 2019 08; 120(8):14004-14016.